Chris: I realize some of the items on JP's lists are out of date because Gerald has not talked about them recently or has changed their time frame. But that is sort of the point. JP's list is an attempt to keep score on the accuracy and consistency of Gerald's milestone statements.

I don't think JP is wrong for reminding us of what Gerald says now compared to what Gerald has said in the past. It's an important indicator for shareholders who are speculating on the company's success.

But inconsistencies in small biotech CEO's comments are not uncommon. It is a business that is subject to perpetual change and CEOs must constantly adjust their navigation. I get that. That's why I'm still invested in AMBS and why I am still giving Gerald the benefit of the doubt.

But at some point small biotech companies must DELIVER if they are to sustain themselves and grow. We are all waiting for several concrete catalysts in the coming 2 months that will greatly move the stock price upward. If that happens, no one will care about Gerald's changing comments in 2013 and 2014. However, if concrete catalysts don't appear in the next 2 months as we'd all hoped.....JP's lists may tell the tale of why AMBS always seems to be undervalued.